Medical Developments International Ltd.’s stock plummets on USA update

medical research

USA Update: Medical Developments International Ltd. (ASX: MVP), which is one of Australia’s leading specialised healthcare companies, witnessed its stock plummet by 19.5% to A$4.71 as on July 25, 2018 after U.S. Food and Drug Administration (FDA) did not approve the sale of its Penthrox “green whistle” pain management product in U.S. As a result, the clinical program for Penthrox will be put on hold based on outstanding issues and concerns that will be provided in a letter. Further, the letter is expected to be delivered within the next 2 months. The company has a market capitalization of $346 million. The company provides a range of products in the areas of pain management, asthma and resuscitation, along with veterinary equipment since 1971. The company has strong focus on expanding into international healthcare markets. Meanwhile, MVP stock has fallen 13.97% in three months as on July 24, 2018 and is trading at a very high P/E.

[pluginops_form template_id=’23834′ ]

 

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report